136 related articles for article (PubMed ID: 29214578)
1. Cost-Effectiveness Methods and Newborn Screening Assessment.
Castilla-Rodríguez I; Vallejo-Torres L; Couce ML; Valcárcel-Nazco C; Mar J; Serrano-Aguilar P
Adv Exp Med Biol; 2017; 1031():267-281. PubMed ID: 29214578
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of a National Newborn Screening Program for Biotinidase Deficiency.
Vallejo-Torres L; Castilla I; Couce ML; Pérez-Cerdá C; Martín-Hernández E; Pineda M; Campistol J; Arrospide A; Morris S; Serrano-Aguilar P
Pediatrics; 2015 Aug; 136(2):e424-32. PubMed ID: 26169436
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of long-term impacts of universal newborn hearing screening.
Chiou ST; Lung HL; Chen LS; Yen AM; Fann JC; Chiu SY; Chen HH
Int J Audiol; 2017 Jan; 56(1):46-52. PubMed ID: 27598544
[TBL] [Abstract][Full Text] [Related]
4. The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
Grosse SD; Thompson JD; Ding Y; Glass M
Milbank Q; 2016 Jun; 94(2):366-91. PubMed ID: 27265561
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of expanded newborn screening in Texas.
Tiwana SK; Rascati KL; Park H
Value Health; 2012; 15(5):613-21. PubMed ID: 22867769
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness methods of newborn screening assessment.].
Valcárcel Nazco C; García Pérez L; Linertová R; Castilla I; Vallejo Torres L; Ramos Goñi JM; Labrador Cañadas V; Couce ML; Espada Sáenz-Torres M; Dulín Íñiguez E; Posada M; Imaz Iglesia I; Serrano Aguilar P
Rev Esp Salud Publica; 2021 Jan; 95():. PubMed ID: 33496278
[TBL] [Abstract][Full Text] [Related]
7. The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment: Mexico and the United States.
Rothschild MI; Russ R; Brennan KA; Williams CJ; Berrones D; Patel B; Martinez-Castellanos MA; Fernandes A; Hubbard GB; Chan RVP; Yang Z; Olsen TW
Am J Ophthalmol; 2016 Aug; 168():110-121. PubMed ID: 27130372
[TBL] [Abstract][Full Text] [Related]
8. An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.
Thiboonboon K; Leelahavarong P; Wattanasirichaigoon D; Vatanavicharn N; Wasant P; Shotelersuk V; Pangkanon S; Kuptanon C; Chaisomchit S; Teerawattananon Y
PLoS One; 2015; 10(8):e0134782. PubMed ID: 26258410
[TBL] [Abstract][Full Text] [Related]
9. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of newborn screening for severe combined immunodeficiency.
Van der Ploeg CPB; Blom M; Bredius RGM; van der Burg M; Schielen PCJI; Verkerk PH; Van den Akker-van Marle ME
Eur J Pediatr; 2019 May; 178(5):721-729. PubMed ID: 30805731
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness and test-performance factors in relation to universal newborn hearing screening.
Gorga MP; Neely ST
Ment Retard Dev Disabil Res Rev; 2003; 9(2):103-8. PubMed ID: 12784228
[TBL] [Abstract][Full Text] [Related]
12. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders.
Schlander M; Garattini S; Holm S; Kolominsky-Rabas P; Nord E; Persson U; Postma M; Richardson J; Simoens S; de Solà Morales O; Tolley K; Toumi M
J Comp Eff Res; 2014 Jul; 3(4):399-422. PubMed ID: 25275236
[TBL] [Abstract][Full Text] [Related]
13. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis.
Landfeldt E; Alfredsson L; Straub V; Lochmüller H; Bushby K; Lindgren P
Pharmacoeconomics; 2017 Feb; 35(2):249-258. PubMed ID: 27798808
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive cost-utility analysis of newborn screening strategies.
Carroll AE; Downs SM
Pediatrics; 2006 May; 117(5 Pt 2):S287-95. PubMed ID: 16735255
[TBL] [Abstract][Full Text] [Related]
15. Economic model of a birth cohort screening program for hepatitis C virus.
McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.
Cipriano LE; Rupar CA; Zaric GS
Value Health; 2007; 10(2):83-97. PubMed ID: 17391418
[TBL] [Abstract][Full Text] [Related]
17. Neonatal hearing screening: modelling cost and effectiveness of hospital- and community-based screening.
Grill E; Uus K; Hessel F; Davies L; Taylor RS; Wasem J; Bamford J
BMC Health Serv Res; 2006 Feb; 6():14. PubMed ID: 16504089
[TBL] [Abstract][Full Text] [Related]
18. Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis.
Aranda-Reneo I; Rodríguez-Sánchez B; Peña-Longobardo LM; Oliva-Moreno J; López-Bastida J
Value Health; 2021 Mar; 24(3):431-442. PubMed ID: 33641778
[TBL] [Abstract][Full Text] [Related]
19. Towards the automated economic assessment of newborn screening for rare diseases.
Prieto-González D; Castilla-Rodríguez I; González E; Couce ML
J Biomed Inform; 2019 Jul; 95():103216. PubMed ID: 31128259
[TBL] [Abstract][Full Text] [Related]
20. Pulse oximetry as a screening test for congenital heart defects in newborn infants: a cost-effectiveness analysis.
Roberts TE; Barton PM; Auguste PE; Middleton LJ; Furmston AT; Ewer AK
Arch Dis Child; 2012 Mar; 97(3):221-6. PubMed ID: 22247242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
